Alzheimer's ‘Escapees': Scientists Seek Clues From Those Who Evade Genetic Fate
Scientists are digging into why a few people escape the rarest form of Alzheimer’s, which is inherited and strikes young. Every so often, someone dodges their family’s genetic fate.
Why a New Alzheimer's Drug Is Having a Slow US Debut
The first drug to show that it slows Alzheimer’s is on sale, but treatment for most patients is still several months away. Experts say scant coverage of the drug and a long setup time needed by health systems are two main factors behind the slow debut. The U.S. Food and Drug Administration approved Leqembi from Japanese drugmaker Eisai in early...
New Alzheimer's Drug Slows Progression of Disease But It Comes With Caveats
A new Alzheimer’s drug is hitting the market with experts voicing a lot of caution.
Probe: Alzheimer's Drug Approval ‘Rife With Irregularities'
The Biogen company wanted to set an “unjustifiably high” initial price of $56,000 a year for the Alzheimer’s drug, investigators said.
Alzheimer's Treatment Shows Promise in Early Results of Study, Drugmaker Says
Biogen and Japan’s Eisai Co. said early results showed that the treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo after 18 months of the infused treatment
Even Simple Exercise May Help Aging Brain, Study Hints
New research hints that even simple exercise just might help seniors with mild memory problems.
Biogen Cuts the Price Tag on Its Alzheimer's Drug in Half
Biogen is slashing the price of its Alzheimer’s treatment months after the drug debuted to widespread criticism for an initial cost that can reach $56,000 annually
Alzheimer's Drug Cited as Medicare Premium Jumps by $21.60
Medicare’s “Part B” outpatient premium will jump by $21.60 a month in 2022, one of the largest increases ever.
In Quiet Debut, Alzheimer's Drug Finds Questions, Skepticism
Persistent concerns about the first new Alzheimer’s treatment in more than 20 years are curbing access more than four months after regulators approved it.